← boardnext 2027-10next 2030-08
HRMY
Zynerba Pharmaceuticals, Inc.distress 0/10 · well-funded / low risk$34.51-1%today-15% from 52w high
Lead: idiopathic hypersomnia
Revenue
$215M
Liquidity
$870M
Runway
—
Shares 1y
+1%
Price & events
-6.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.0%
1D
+2.9%
1W
+1.0%
1M
+7.6%
3M
-6.3%
6M
-7.3%
1Y
+3.0%
2Y
+17.3%
5Y
-2.6%
All
Overview
- Market Cap
- $2.00B
- Enterprise Value
- $1.55B
- Volume
- 30.26K
- 52 Week Range
- $25.90 – $40.51
- Total Shares
- 57.89M
- Float Shares
- 51.73M
- Short %
- 10.66%
- % Held by Insiders
- 11.69%
- % Held by Institutions
- 103.17%
- RVOL
- 0.03x
- Beta
- 0.94
Pipeline stages · 3 programs
HBS-301 tablet
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pitolisant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ZYN002 - Cannabidiol Transdermal Gel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-10 Estimated 50% readout ~2027-12-15 | Phase 3 | HBS-301 tablet | Idiopathic Hypersomnia | — | recruiting |
| 2027-10 Estimated 50% readout ~2027-12-15 | Phase 3 | HBS-301 | EDS, Cataplexy, Fatigue, Narcolepsy | — | recruiting |
| 2030-08 Estimated 50% readout ~2030-10-15 | Phase 3 | Pitolisant | Prader-Willi Syndrome | — | enrolling by invitation |
| 2026-07-01 | Phase 3 | Pitolisant tablet | Prader-Willi Syndrome | — | recruiting |
| 2026-06-30 | Phase 2/3 | ZYN002 - Cannabidiol Transdermal Gelfast trackorphan | Fragile X Syndrome | — | active not recruiting |
Catalyst news & presentations · 30
- 2028Guided 40%PDUFAPDUFApitolisant HD · anticipated PDUFA dateSEC 8-K
- 2027Guided 40%readoutPhase 3pitolisant HD · Topline data from ONSTRIDE 1 and ONSTRIDE 2 trialsSEC 8-K
- 1H 2027Guided 55%readoutPhase 3EPX-100 · Topline data from ARGUS studySEC 8-K
- 1Q 2027Guided 70%PDUFAPDUFApitolisant GR · anticipated PDUFA dateSEC 8-K
- 2H 2026Guided 55%readoutPhase 3pitolisant · Phase 3 topline data readoutSEC 8-K
- 2026Guided 40%PDUFAPDUFApitolisant GR · Potential PDUFA date.SEC 8-K
- 2026Guided 40%readoutPhase 1BP1.15205 · Phase 1 clinical dataSEC 8-K
- 2026Guided 40%readoutPhase 3EPX-100 · Topline data from ARGUS studySEC 8-K
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026readoutPhase 1BP1.15205 · Phase 1 clinical data for orexin-2 agonist.SEC 8-K
- mid-2026readoutPhase 1BP1.15205 · Phase 1 clinical PK dataSEC 8-K
- 2Q 2026regulatory submissionFiled (NDA/BLA)pitolisant GR · NDA submission for gastro-resistant formulationSEC 8-K
- mid-2026readoutPhase 1BP-205 · Phase 1 clinical PK data on track for mid-2026SEC 8-K
- Q4 2025trial initiationsecondaryPhase 3pitolisant HD · Initiate Phase 3 registrational trial for pitolisant HD in idiopathic hypersomniaSEC 8-K
- Q4 2025trial initiationsecondaryPhase 3Initiate Phase 3 trial pending positive ZYN002 data.SEC 8-K
- Q4 2025trial initiationsecondaryPhase 1BP1.15205 · First-in-human study initiationSEC 8-K
- 2025trial initiationsecondaryPhase 3ZYN-002 · Initiate pivotal Phase 3 trial in 22q deletion syndrome in 2025SEC 8-K
- Q4 2025readoutpitolisant GR · Topline data from pivotal BE study.SEC 8-K
- Q4 2025trial initiationsecondaryPhase 3ZYN002 · Initiate Phase 3 registrational trial in 22q.SEC 8-K
- December 2025conferencedata presentationsecondaryPhase 3EPX-100 · Data from ARGUS open label extension at AES meetingSEC 8-K
- Q3 2025readoutPitolisant-GR · Topline data from pivotal bioequivalence study.SEC 8-K
- Q3 2025trial initiationsecondaryPhase 1BP1.15205 · First-in-human study for BP1.15205SEC 8-K
- Q3 2025readoutPhase 3ZYN002 · Topline data readout from pivotal Phase 3 trial in fragile X syndromeSEC 8-K
- mid-2025readoutPhase 3ZYN-002 · Topline data from pivotal Phase 3 trial in Fragile X syndrome expected mid-2025SEC 8-K
- Q2 2025conferencedata presentationsecondaryBP1.15205 · Preclinical data for BP1.15205 (OX2R agonist) to be presented at SLEEP 2025SEC 8-K
- mid-2025regulatory submissionFiled (NDA/BLA)orexin-2 agonist · IND submission for novel orexin-2 agonistSEC 8-K
- 2025-06-05partnershippitolisant hydrochloride · Settlement agreement with Lupin resolving patent litigation; Lupin receives license to launch generic no earlier than January 2030SEC 8-K
- Q1 2025filing acceptanceFiled (NDA/BLA)pitolisant · FDA decision on file acceptance of pitolisant sNDA for idiopathic hypersomniaSEC 8-K
- Fourth Quarter 2024regulatory submissionFiled (NDA/BLA)pitolisant · On track to submit sNDA for pitolisant in idiopathic hypersomniaSEC 8-K
- Q4 2024trial initiationsecondaryPhase 3EPX-100 · Initiate pivotal Phase 3 trial in Lennox-Gastaut syndrome in Q4 2024SEC 8-K
Approved drugs (1)
- WAKIXPITOLISANT HYDROCHLORIDE2020 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $45 (+30% upside) · 11 analysts
- 2026-07-16HC Wainwright & Co.Buy
- 2026-06-30Deutsche BankHold
- 2026-05-08Truist SecuritiesHold
- 2026-02-25B of A SecuritiesUnderperform
- 2026-02-25HC Wainwright & Co.Buy
- 2026-02-25NeedhamBuy
Competitors — idiopathic hypersomnia
Recent news
- 2026-07-23Harmony Biosciences interim principal financial officer Stephen Mollichella files initial beneficial ownership statement - Bitget
- 2026-07-22Harmony Biosciences (HRMY) officer details stock and option holdings - Stock Titan
- 2026-07-22Harmony Biosciences (HRMY) Soars 10.0%: Is Further Upside Left in the Stock? - Yahoo! Finance Canada
- 2026-07-22Harmony Biosciences Holdings Jumps 9.6% Amid Sector-Wide Rally - AlphaStreet
- 2026-07-21Harmony Biosciences Holdings Jumps 9.6% Amid Sector-Wide Rally - AlphaStreet
- 2026-07-21Harmony Biosciences to report Q2 2026 results on August 4 - scanx.trade
- 2026-07-21Harmony Biosciences will host a live Q2 results webcast on Aug. 4 - Stock Titan
- 2026-07-21Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026 - Yahoo Finance Singapore
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.